Working… Menu

Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT) (HIT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00790894
Recruitment Status : Terminated (The low accrual rate of the study (25% of the expected accrual rate))
First Posted : November 14, 2008
Last Update Posted : May 18, 2011
Information provided by:
Hellenic Cooperative Oncology Group